2-(1,3-二氧代异吲哚啉-2-基)-N-苯乙酰胺和2-(3,4-二氢异喹啉-1-基)异吲哚-1,3-二酮类单胺氧化酶(MAO)和胆碱酯酶(ChE)抑制剂的设计、合成和生物活性研究
收稿日期: 2023-11-24
修回日期: 2024-01-22
网络出版日期: 2024-03-13
基金资助
福建省药物新靶点研究重点实验室开放课题资助(FJ-YW-2023KF04); 国家级大学生创新创业训练计划(202310340048)
Design, Synthesis and Biological Activity Studies of 2-(1,3-Dioxoiso-indolin-2-yl)-N-phenethylacetamide and 2-(3,4-Dihydroisoquinolin-1-yl)isoindole-1,3-dione as Monoamine Oxidase (MAO) and Cholinesterase (ChE) Inhibitors
Received date: 2023-11-24
Revised date: 2024-01-22
Online published: 2024-03-13
Supported by
Fujian Provincial Key Laboratory of Innovative Drug Target Research(FJ-YW-2023KF04); National College Student Innovation and Entrepreneurship Training Program(202310340048)
合成了一系列2-(1,3-二氧代异吲哚啉-2-基)-N-苯乙酰胺和2-(3,4-二氢异喹啉-1-基)异吲哚-1,3-二酮衍生物, 并评价了它们抑制单胺氧化酶(MAO)和胆碱酯酶(ChE)生物活性. 实验结果显示, 所有的化合物对单胺氧化酶具有一定的抑制活性. 再分别进行单胺氧化酶A (MAO-A)和单胺氧化酶B (MAO-B)抑制活性研究, 发现所有化合物对MAO-B显示比较好的抑制活性, 对MAO-A显示弱的抑制活性. 其中, 2-(1,3-二氧代异吲哚-2-基)-N-(4-氟苯基乙基)乙酰胺(2h)和2-((7-甲氧基-3,4-二氢异喹啉-1-基)甲基)异吲哚-1,3-二酮(3d)显示最好的抑制MAO-A和MAO-B作用, 对MAO的IC50值分别为(3.87±0.59)和(3.35±0.53) μmol/L. 细胞毒性实验结果显示, 抑制活性比较好的化合物对L929细胞没有细胞毒性. 化合物2h和3d分子对接的结果表明, 化合物2h和3d与MAO-A和MAO-B之间存在明显的相互作用. 另外, 所有的化合物对乙酰胆碱酯酶(AChE)和丁酰胆碱酯酶(BuChE)显示比较弱的抑制活性.
胡懿鸣 , 许嘉宇 , 汤敏 , 刘雅雯 , 关丽萍 , 金晴昊 . 2-(1,3-二氧代异吲哚啉-2-基)-N-苯乙酰胺和2-(3,4-二氢异喹啉-1-基)异吲哚-1,3-二酮类单胺氧化酶(MAO)和胆碱酯酶(ChE)抑制剂的设计、合成和生物活性研究[J]. 有机化学, 2024 , 44(6) : 1907 -1919 . DOI: 10.6023/cjoc202311027
A series of 2-(1,3-dioxoisoindolin-2-yl)-N-phenethylacetamide and 2-(3,4-dihydroisoquinolin-1-yl)isoindole- 1,3-dione derivatives were synthesized and their biological activities of monoamine oxidase (MAO) and cholinesterase (ChE) inhibition were evaluated. The experimental results showed that all compounds exhibited certain inhibitory activity against MAOs. Upon separate monoamine oxidase A (MAO-A) and monoamine oxidase A (MAO-B) activity were studied, the compounds displayed better inhibition activity against MAO-B and weaker inhibition activity against MAO-A. Among these, 2-(1,3-dioxoisoindolin-2-yl)-N-(4-fluorophenethyl)acetamide (2h) and 2-((7-methoxy-3,4-dihydroisoquinolin-1-yl)methyl)iso- indoline-1,3-dione (3d) exhibited the most significant inhibition of MAO-A and MAO-B, with IC50 values of (3.87±0.59) and (3.35±0.53) μmol/L towards MAO, respectively. Results from cytotoxicity assays indicated that compounds with good inhi-bitory activity showed no cytotoxicity against L929 cells. Molecular docking of compounds 2h and 3d revealed significant interactions between the active analogs and amino acid residues of the protein receptors. Additionally, all compounds exhibited relatively weak inhibition activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE).
| [1] | Stefanie, A.; Iyengar, R. E.; Rebecca, S.; Bencie, N. M.; Jeenu, A. M.; Rahul, E.; Adrien, A. J. Drug targeting. 2020, 28, 10. |
| [2] | Lehn, A.; Gelauff, J.; Hoeritzauer, I.; Ludwig, L.; McWhirter, L.; Williams, S.; Gardiner, P.; Carson, A.; Stone, J. J. Neurol. 2016, 263, 611. |
| [3] | Mishra, A.; Bandopadhyay, R.; Singh, P. K.; Mishra, P. S.; Sharma, N.; Khurana, N. Metab. Brain Dis. 2021, 36, 1591. |
| [4] | Furmark, T. Isr. Ann. Psychiatry Relat. Discip. 2009, 46, 5. |
| [5] | Lane, C. A.; Hardy, J.; Schott, J. M. Eur. J. Neurol. 2018, 25, 59. |
| [6] | Mantzavinos, V.; Alexiou, A. Curr. Alzheimer Res. 2017, 14, 1149. |
| [7] | Weller, J.; Budson, A. Eur. J. Neurol. 2019, 5, 43. |
| [8] | Li, Y. Y.; Tang, Q.; Zheng, L. F.; He, D.; Jian, S.; Zhang, M. Eur. J. Med. Chem. 2020, 166, 49. |
| [9] | Xing, S.; Sun, H. P. Pharm. Prog. 2023, 47, 179. (in Chinese) |
| [9] | (邢帅帅, 孙昊鹏, 药学进展, 2023, 47, 179.) |
| [10] | Marucci, G.; Buccioni, M.; Ben, D. D.; Lambertucci, C.; Volpinim, R.; Amenta, F. J. Neurol. 2021, 190, 108352. |
| [11] | Anand, P.; Singh, B. Arch. Pharm. Res. 2013, 36, 375. |
| [12] | Caraci, F.; Copani, A.; Nicoletti, F.; Drago, F. Eur. J. Pharmacol. 2010, 626, 64. |
| [13] | Tune, L. E. Eur. J. Pharmacol. 2008, 8, 91. |
| [14] | Liu, Y. H.; Xu, H. D.; Dong, X. H.; Zhang, N.; Luo, X. T.; Zhang, H.; Liu, B. Chin. Herb. Med. 2023, 7, 1836. (in Chinese) |
| [14] | (刘彦宏, 徐红丹, 董晓红, 张宁, 罗孝廷, 张红, 刘斌, 中药材, 2023, 7, 1836.) |
| [15] | Liu, F.; Zhou, Y. J. Clin. Psychosom. Dis. 2007, 3, 251. (in Chinese) |
| [15] | (刘峰, 周艳, 临床心身疾病杂志, 2007, 3, 251.) |
| [16] | Bhawna-Kumar, A.; Bhatia, M.; Kapoor, A.; Kumar, P.; Kumar, S. Eur. J. Med. Chem. 2022, 242, 114655. |
| [17] | ?zdemir, Z.; Alag?z, M. A.; Bah?ecio?lu, ?. F.; G?k, S. Curr. Med. Chem. 2021, 28, 6045. |
| [18] | Carradori, S.; Secci, D.; Petzer, J. P. Expert Opin. Ther. Pat. 2018, 3, 211. |
| [19] | Zhang, N. Med. Theory Pract. 2015, 28, 1713. (in Chinese) |
| [19] | (张娜, 医学理论与实践, 2015, 28, 1713.) |
| [20] | Mzezewa, S. C.; Omoruyi, S. I.; Zondagh, L. S.; Malan, S. F.; Ekpo, O. E.; Joubert, J. J. Enzyme Inhib. Med. Chem. 2021, 36, 1607. |
| [21] | Sang, Z. P.; Song, Q.; Cao, Z. C.; Deng, Y.; Zhang, L. J. Enzyme Inhib. Med. Chem. 2022, 37, 69. |
| [22] | Das, T.; Saha, S. C.; Sunita, K. S. Afr. J. Bot. 2022, 11, 146. |
| [23] | Zhang, H. H. M.S. Thesis, Lanzhou University, Lanzhou, 2022. (in Chinese) |
| [23] | (张红花, 硕士论文, 兰州大学, 兰州, 2022.) |
| [24] | Unzeta, M.; Esteban, G.; Bolea, I.; Fogel, W. A.; Ramsay, R. R.; Youdim, M. B.; Tipton, K. F.; Marco-Contelles, J. Front. Neurosci. 2016, 10, 205. |
| [25] | Zhang, M.; Zhang, H.; Zheng, J. X.; Mo, H.; Xia, K. F.; Jian, S. G. Int. J. Mol. Sci. 2018, 19, 3446. |
| [26] | Plazas, E.; Avila, M. C.; Mu?oz, D. R.; Cuca, S. L. E. Pharmacol. Res. 2022, 177, 106126. |
| [27] | Zou, X. H.; Fu, X. Q.; Wang, W. W. Cardiovasc. Dis. J. Integr. Tradit. Chin. West Med. 2023, 21, 3497. (in Chinese) |
| [27] | (邹旭欢, 付雪琴, 王玮玮, 中西医结合心脑血管病杂志, 2023, 21, 3497.) |
| [28] | Bonnet, U. CNS Drug Rev. 2003, 9, 140. |
| [29] | Behlke, L. M.; Lenze, E. J.; Carney, R. M. CNS Drugs 2020, 34, 1133. |
| [30] | Liang, Y.; Zhang, L.; Zeng, Z. C. Chin. J. New Drugs 2018, 27, 1603. (in Chinese) |
| [30] | (梁瑶, 张蕾, 曾灶昌, 中国新药杂志, 2018, 27, 1603.) |
| [31] | Pan, S. L.; Xie, J.; Qian, F. G.; Wang, J.; Shao, Y. C. Acta Pharm. Sin. 2005, 4, 355. (in Chinese) |
| [31] | (潘胜利, 解静, 钱伏刚, 王峻, 邵衣慈, 药学学报, 2005, 4, 355.) |
| [32] | Verma, S.; Lal, S.; Narang, R.; Sudhakar, K. Chem. Med. Chem. 2023, 18, e202200571. |
| [33] | Teng, P.; Li, C.; Peng, Z.; Anne, M. V.; Nimmagadda, A.; Su, M.; Li, Y.; Sun, X.; Cai, J. Bioorg. Med. Chem. 2018, 26, 3573. |
| [34] | Guan, L. P.; Jin, Q. H.; Tian, G. R.; Chai, K. Y.; Quan, Z. S. J. Pharm. Pharm. Sci. 2007, 10, 254. |
| [35] | P?ssler, U.; Kn?lker, H. J. Alkaloids Chem. Biol. 2011, 70, 79. |
| [36] | Bhadra, K.; Kumar, G. S. Mini. Rev. Med. Chem. 2010, 10, 1235. |
| [37] | Jason, D. J. M.; Norman, H.; Rigdon, G. A. J. Med. Chem. 2016, 39, 149. |
| [38] | Kong, X. P.; Chen, Z. Z.; Xia, Y. J.; Ren, H. Q.; Dong, T. X.; Zhan, H. Q. J. Liaoning Univ. Tradit. Chin. Med. 2021, 23, 35. (in Chinese) |
| [38] | (孔祥鹏, 陈志从, 夏英杰, 任海琴, 董婷霞, 詹华强, 辽宁中医药大学学报, 2021, 23, 35.) |
| [39] | Guo, H. M.; Lu, Z. H.; Chen, S. Q.; Yu, Y. Asian J. Chem. 2015, 10, 3651. |
| [40] | Xi, M. Y.; Jia, J. M.; Sun, H. P.; Sun, Z. Y.; Jiang, J. W.; Wang, Y. J.; Zhang, M. Y. J. Med. Chem. 2013, 56, 7925. |
| [41] | Gan, L. L.; Gan, Z. J.; Gan, Z. J.; Dan, Y. R.; Zhang, P. M. J. Med. Chem. 2021, 64, 1018. |
| [42] | Grenier, D.; Audebert, S.; Preto, J.; Guichou, J. F.; Krimm, I. Expert Opin. Drug Discovery 2023, 18, 987. |
| [43] | Xia, M. L.; Niu, W. W.; Lin, D. Z. J. Tianjin Med. Univ. 2023, 29, 349. (in Chinese) |
| [43] | (夏梦琳, 牛菀菀, 林道正, 天津医科大学学报, 2023, 29, 349.) |
| [44] | Hansen, M.; Bonner, L. A.; Cueva, J. P.; Maglathlin, R.; Nichols, D. E. ACS Chem. Neurosci. 2013, 4, 96. |
| [45] | Ellman, G. L.; Courteny, K. D.; Andres, V.; Feather, R. M.. Biochem. Pharmacol. 1961, 7, 88. |
| [46] | Paulson, J. R.; Vander, E. R.; Dillinger, E.; Luedeman, M. E.; Usman, B. Chromosome Res. 2022, 30, 351. |
/
| 〈 |
|
〉 |
